Several formulations of fentanyl citrate have gone into shortage, the TGA says
The TGA updated its website today to advise that Hospira’s DBL Fentanyl 100microgram/2mL (as citrate) injection USP ampoule has gone into shortage, with supply expected on 7 July.
It joins several other Fentanyl products which have gone into shortage over the last few days.
The reason given for the shortage is, “unexpected increase in demand,” which is also the reason given for new shortages of the following:
- Fentanyl GH Solution for Injection 100microgram/2mL ampoule (shortage until 30 June 2017)
- Fentanyl GH Solution for Injection 500 microgram/10 mL ampoule (to 30 June)
- Astrazeneca Fentanyl 100 microgram/2mL (as citrate) injection ampoule (to 17 June); and
- Astrazeneca Fentanyl 500 microgram/10mL (as citrate) injection ampoule (to 17 June).
Also in shortage for manufacturing reasons are:
- Aspen Fentanyl fentanyl (as citrate) 100 microgram/2 mL solution for injection (to 17 July); and
- Aspen Fentanyl fentanyl (as citrate) 500 microgram/10 mL solution for injection.